SEC Form 4 · accession 0001232524-16-000281
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Seamus Mulligan
Director
Period of report
May 24, 2016
Accepted (ET)
May 26, 2016 · 5:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF2 | May 24, 2016 | S | 1,400 | $148.6464 | D | 1,101,179 | D | |
| Ordinary SharesF3 | May 24, 2016 | S | 11,888 | $149.6377 | D | 1,089,291 | D | |
| Ordinary SharesF4 | May 24, 2016 | S | 9,954 | $150.7238 | D | 1,079,337 | D | |
| Ordinary SharesF5 | May 24, 2016 | S | 4,726 | $151.51 | D | 1,074,611 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $148.18 to $149.14. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F3Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $149.18 to $150.17. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F4Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $150.18 to $151.17. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F5Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $151.18 to $151.77. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.